Effects of Shuangbai Jianpi capsules combined with Mesalazine enteric-coated tablets in treatment of patients with ulcerative colitis
Objective:To observe effects of Shuangbai Jianpi capsules combined with Mesalazine enteric-coated tablets in treatment of patients with ulcerative colitis.Methods:A prospective study was conducted on 82 patients with ulcerative colitis admitted to the hospital from February 2021 to February 2023.According to the random number table method,they were divided into study group and control group,41 cases in each group.The control group was treated with Mesalazine Enteric-coated tablets,while the study group was treated with Shuangbai Jianpi capsules on the basis of that of the control group.The total effective rate of treatment,the Mayo disease activity index score,the serum inflammatory indexes[C-reactive protein(CRP),soluble intercellular adhesion molecule-1(sICAM-1),soluble receptor for advanced glycation end products(sRAGE)]levels,the colon ulcer surface diameter,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 95.12% ,which was significantly higher than 78.05% of the control group,and the difference was statistically significant(P<0.05).After the treatment,the scores of Mayo disease activity index and the levels of serum CRP,sICAM-1,sRAGE and other inflammatory indexes in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the colonic ulcer surface diameter in the two groups were shorter than those before treatment,that in the study group was shorter than that in the control group,and the differences were statistically significant(P<0.05).During the treatment,no obvious adverse reactions occurred in the two groups.Conclusions:Shuangbai Jianpi capsules combined with Mesalazine enteric-coated tablets in the treatment of the patients with ulcerative colitis,can improve the total effective rate of treatment,reduce the Mayo disease activity index score and the serum CRP,sICAM-1,sRAGE levels,and shorten the colonic ulcer surface diameter.Moreover,it is superior to single Mesalazine enteric-coated tablets treatment.
万方数据
维普
